Last reviewed · How we verify
NCT04007211
Pivotal Clinical Study to Assess the Anti-adhesive Effect and Safety of ABT13107 Applied to Postoperative Intrauterine
NA trial testing ABT13107 in Postoperative Adhesion of Uterus in 192 participants. Completed in 29 August 2018.
29 August 2018
Quick facts
| Lead sponsor | Medy-Tox |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 192 |
| Start date | 27 February 2017 |
| Primary completion | 29 August 2018 |
| Estimated completion | 29 August 2018 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- ABT13107
- Hyalobarrier
Conditions studied
- Postoperative Adhesion of Uterus — all drugs for Postoperative Adhesion of Uterus →
Sponsor
Medy-Tox — full company profile →
Who can join
Adults 19 to 70, female only, with Postoperative Adhesion of Uterus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is intended to evaluate the efficacy and safety of ABT13107 compared to Hyalobarrier applied to postoperative intrauterine.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Biomaterializing the advances in uterine tissue engineering.
Wei Z, Hu Y, He X, Ling W, et al · · 2022 · cited 13× · PMID 36536678 · DOI 10.1016/j.isci.2022.105657 -
A New Thermo-Responsive Hyaluronic Acid Sol-Gel to Prevent Intrauterine Adhesions after Hysteroscopic Surgery: A Randomized, Non-Inferiority Trial.
Lee DY, Lee SR, Kim SK, Joo JK, et al · · 2020 · cited 11× · PMID 32975061 · DOI 10.3349/ymj.2020.61.10.868
Verify or expand the search:
- PubMed search for NCT04007211
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Medy-Tox trials
Trials by the same sponsor.
- NCT05195112 — Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat · Phase 3 · completed
- NCT04157686 — MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) · Phase 3 · completed
- NCT04281745 — Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX® · Phase 4 · unknown
- NCT04144049 — A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat · Phase 2 · completed
- NCT04143854 — Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04007211 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medy-Tox
- Last refreshed: 25 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04007211.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing